Initiation of anti-TNF therapy within 3 weeks of LTBI treatment in patients with immune-mediated inflammatory diseases

Y. Yeo, K. W. Jo, S. D. Lee, W. S. Kim, D. S. Kim, T. S. Shim (Seoul, Republic Of Korea)

Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Session: Tuberculosis: from epidemiology to therapy 3
Session type: Thematic Poster Session
Number: 2684
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Yeo, K. W. Jo, S. D. Lee, W. S. Kim, D. S. Kim, T. S. Shim (Seoul, Republic Of Korea). Initiation of anti-TNF therapy within 3 weeks of LTBI treatment in patients with immune-mediated inflammatory diseases. Eur Respir J 2014; 44: Suppl. 58, 2684

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Prevention of latent TB reactivation in rheumatology patients prior to anti-TNF therapy: Evaluation of a risk stratification strategy in a low prevalence area
Source: International Congress 2015 – Screening strategies in TB
Year: 2015

Diagnosing latent tuberculosis in immunocompromised patients measuring blood IP-10 production capacity: An analysis of chronic renal faulire patients
Source: International Congress 2015 – Screening strategies in TB
Year: 2015


A combinatorial dual-immunoassay predicts reactivation risk for patients with previously incomplete treatment for latent tuberculosis infection
Source: International Congress 2016 – Active and latent tuberculosis: biomarkers
Year: 2016


Treatment for latent tuberculosis infection in migrants carries a low risk of hepatotoxicity
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014


The value of immunological methods in the diagnosis of tuberculosis in patients with HIV
Source: International Congress 2015 – Screening strategies in TB
Year: 2015


LATE-BREAKING ABSTRACT: The performance of flow cytometry in the diagnosis of latent tuberculosis infection in patients under treatment with anti-TNFa and other biological agents
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations
Year: 2013


Anti-TNF-alpha therapy in patients with latent tuberculosis incidence
Source: International Congress 2015 – Screening strategies in TB
Year: 2015

Diagnosis of latent tuberculosis infection in children with the useof different immunological methods
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016


Clinical evaluation of several biomarkers including IFN-γ for the diagnosis of tuberculosis infection
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016

Evaluate the potential of IP-10 as biomarker for the MDR-TB treatment outcome
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013


Tuberculin skin test or interferon gamma release assay - How to detect latent tuberculosis infection in sarcoidosis patients?
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015

Correlation between tuberculin-skin-test and interferon-gamma-release-assays with risks factors for tuberculosis infection
Source: Annual Congress 2013 –Immunological diagnosis of tuberculosis and latent tuberculosis infection
Year: 2013


Study of inflammatory markers in sputum positive patients of pulmonary tuberculosis and its response to anti-tubercular treatment
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016


Risk of tuberculosis in dialysis population: Revising the predictive value of interferon-gamma releasing assay
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016

Use of an ELISPOT interferon-gamma release assay for screening of end-stage renal failure contacts in haemodialysis centres
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014

New-immigrant screening for latent tuberculosis infection: Reasons for non-treatment
Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Year: 2013



Tuberculin skin testing to the IGRA positive contacts of infectious tuberculosis cases for the treatment of latent tuberculosis infection
Source: International Congress 2015 – Latent TB infection and screening
Year: 2015


Latent TB infection in health care TB workers
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014


Tuberculosis in patients receiving treatment of TNF-alpha inhibitors
Source: International Congress 2015 – Case series and clinical conundrums in TB
Year: 2015


The effect of smoking on QuantiFERON results in diagnosis of latent tuberculosis infection
Source: International Congress 2016 – Latent tuberculosis infection
Year: 2016